BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier  
The applicant Krka, d.d., Novomesto  submitted on  29 September 2006 an application for Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Zalasta,  in  accordance  with  the 
centralised procedure falling within the scope of the Annex to Regulation (EC) 726/2004 under Article 
3 (3) – ‘Generic of a Centrally authorised product’. 
Zalasta 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg tablets and Zalasta  5 mg, 10 mg, 15 mg, and 
20 mg orodispersible tablets  
The application legal basis for these presentations refer to Article 10(1). 
The chosen reference product is: 
Tablets 
■ Reference medicinal product which is or has been authorised for not less than 6/10 
years in the EEA:  
(cid:131) Product name, strength, pharmaceutical form:Zyprexa 2.5/5/7.5/10/15/20 mg Coated Tablets 
(cid:131) Marketing authorisation holder: Eli Lilly Nederland B.V. 
(cid:131) First authorisation:  Date (yyyy-mm-dd)1996-09-27  Member State 
(EEA)/Community:  EU registration 
■ Reference medicinal product authorised in the Community/Member State  
where the application is made:  
(cid:131) Product name, strength, pharmaceutical form: Zyprexa 2.5/5/7.5/10/15/20 mg Coated Tablets 
(cid:131) Marketing authorisation holder:Eli Lilly Nederland B.V. 
(cid:131) Marketing authorisation number(s): EU/1/96/022 
 ■ Medicinal Product used for bioequivalence study (where applicable) 
(cid:131) Product name, strength, pharmaceutical form:Zyprexa, 10 mg, coated tablets 
(cid:131)  Marketing authorisation holder:Eli Lilly Nederland B.V. 
(cid:131)  Member State of source:Germany 
Orodispersible tablets 
■ Reference medicinal product authorised in the Community/Member State  
where the application is made:  
(cid:131) Product name, strength, pharmaceutical form:Zyprexa Velotab 5/10/15/20 mg Orodispersible 
Tablets 
(cid:131) Marketing authorisation holder: Eli Lilly Nederland B.V. 
(cid:131) Marketing authorisation number(s): EU/1/99/125 
 ■ Medicinal Product used for bioequivalence study (where applicable) 
(cid:131) Product name, strength, pharmaceutical form:Zyprexa Velotab, 20 mg, orodispersible tablets 
(cid:131)  Marketing authorisation holder:Eli Lilly Nederland B.V. 
(cid:131)  Member State of source:Germany 
Zalasta  7.5 mg orodispersible tablets 
The application legal basis for this presentation refers to Article 10(3). 
■ Reference medicinal product which is or has been authorised for not less than 6/10 
years in the EEA:  
(cid:131) Product name, strength, pharmaceutical form:Zyprexa 2.5/5/7.5/10/15/20 mg Coated Tablets 
(cid:131) Marketing authorisation holder: Eli Lilly Nederland B.V. 
(cid:131) First authorisation:  Date (yyyy-mm-dd)1996-09-27  Member State 
(EEA)/Community:  EU registration 
1/2 
© EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
 
 
 
 
 
 
 
 
            
 
 
 
 
 
 
 
 
 
 
■ Reference medicinal product authorised in the Community/Member State  
where the application is made:  
(cid:131) Product name, strength, pharmaceutical form:Zyprexa Velotab 5/10/15/20 mg Orodispersible 
Tablets 
(cid:131) Marketing authorisation holder: Eli Lilly Nederland B.V. 
(cid:131) Marketing authorisation number(s): EU/1/99/125 
 ■ Medicinal Product used for bioequivalence study (where applicable) 
(cid:131) Product name, strength, pharmaceutical form:Zyprexa Velotab, 20 mg, orodispersible tablets 
(cid:131)  Marketing authorisation holder:Eli Lilly Nederland B.V. 
(cid:131)  Member State of source:Germany 
(cid:132) Difference(s) compared to the reference medicinal product: 
changes in the active substance(s) 
change in therapeutic indications 
change in pharmaceutical form 
change in strength (quantitative change to the active substance(s)) 
change in route of administration 
bioequivalence cannot be demonstrated through 
The Rapporteur appointed by the CHMP and the evaluation team were: 
Rapporteur 
Prof. M. Lipnik-Štangelj 
2. 
Scientific Advice: 
 The applicant did not seek scientific advice at the CHMP. 
3. 
Licensing status: 
Zalasta tablets has been given a Marketing Authorisation in Poland on 30 April 2004, Albania on 11 
July 2006, Macedonia on 28 October 2005,  Serbia and Montenegro on 5 April 2006. 
Zalasta  orodispersible  tablets  was  not  licensed  in  any  country  at  the  time  of  submission  of  the 
application. 
4. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 29 September 2006.  
The procedure started on 25 October 2006. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 16 January 
2007 . 
During  the  meeting  on  19-22  February  2007,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  22 February 2007. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 4 May 
2007. 
The  summary  report  of  the  GCP  inspection  carried  out  at  MDS  Pharma  Services,  Canada 
between 5-9 March 2007 was issued on 6 June 2007. 
The  Rapporteur  circulated  the  Assessment  Report  on  the  applicant’s  responses  to  the  List  of 
Questions to all CHMP members on  14 June 2007.  
During the meeting on 16 – 19 July 2007, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Zalasta on 19 July 2007.  
2/2 
© EMEA 2007 
 
 
 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
